Dental pulp injury caused by trauma or deep caries often leads to inflammation, tissue necrosis, and eventual loss of tooth ...

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic ...

Keros Therapeutics KROS is focused on developing and commercializing novel therapeutics to treat a wide range of patients ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 and TGF-beta, as a treatment for advanced gastric cancer. The green light – ...

Dental pulp injury caused by trauma or deep caries often leads to inflammation, tissue necrosis, and eventual loss of tooth vitality. In severe cases ...

Dental pulp regeneration remains a major clinical challenge. Researchers have discovered that SMAD7 directly forms a ...

Bicara Therapeutics (NASDAQ:BCAX) outlined its clinical and development strategy for its lead bifunctional antibody program, FICERA, during a presentation and fireside chat at TD Cowen’s 46th annual ...

NOVEL heart failure (HF) research has identified a surprising protective signal produced directly by heart muscle cells that may help slow the development of cardiac fibrosis, a key driver of ...

A new 3D model shows that Duchenne gene therapy can repair muscle fibers but fails to shut down the signals that drive scarring.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Biotechnology industry for Wednesday, March 11, 2026. Let’s ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...